Progyny (NASDAQ:PGNY) Price Target Raised to $38.00

Progyny (NASDAQ:PGNY) had its price target boosted by stock analysts at Leerink Partners from $37.00 to $38.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price target indicates a potential upside of 10.69% from the company’s current price.

A number of other brokerages have also recently weighed in on PGNY. KeyCorp increased their target price on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a report on Monday, October 19th. JPMorgan Chase & Co. lifted their price objective on shares of Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, August 21st. Wells Fargo & Company upped their target price on shares of Progyny from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Eleven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Progyny has a consensus rating of “Moderate Buy” and an average target price of $34.92.

Progyny Trading Up 14.0%

Shares of Progyny stock traded up $4.23 during trading hours on Thursday, reaching $34.33. 1,824,614 shares of the company’s stock were exchanged, compared to its average volume of 1,360,782. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 37.31, a price-to-earnings-growth ratio of 2.01 and a beta of 0.97. The company has a fifty day moving average of $27.11 and a 200-day moving average of $24.49. Progyny has a 52-week low of $16.10 and a 52-week high of $35.50.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same quarter last year, the business earned $0.15 EPS. Progyny’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts anticipate that Progyny will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kevin K. Gordon sold 11,500 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the sale, the director owned 6,792 shares in the company, valued at approximately $189,768.48. This represents a 62.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Allison Swartz sold 3,903 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president owned 75,816 shares in the company, valued at approximately $1,978,797.60. This trade represents a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,282 shares of company stock valued at $475,790 in the last three months. Insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new position in Progyny during the second quarter valued at approximately $29,000. Nykredit A S acquired a new position in shares of Progyny during the 2nd quarter worth approximately $38,000. IFP Advisors Inc raised its stake in shares of Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Progyny during the 2nd quarter worth approximately $65,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Progyny in the 2nd quarter valued at approximately $74,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny News Roundup

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Quarterly results topped expectations: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million. Revenue rose 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Progyny Q3 results
• Positive Sentiment: Higher earnings outlook: The company raised its 2026 earnings guidance and provided a fourth-quarter outlook, a key catalyst behind the more favorable analyst commentary. Progyny raises 2026 earnings guidance
• Positive Sentiment: Analysts raised price targets: Citizens JMP lifted its target to $38 and maintained a “market outperform” rating; Cantor Fitzgerald raised its target to $35 and kept an “overweight” rating. Both cited the improved outlook. Citizens JMP target increase
• Positive Sentiment: Growth indicators: A Q3 analysis highlighted new client wins and margin expansion, supporting the case for continued business momentum. Q3 analysis

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.